

FATE THERAPEUTICS INC  
Form 8-K  
November 07, 2018  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 5, 2018

Fate Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

|                                 |              |                     |
|---------------------------------|--------------|---------------------|
| Delaware                        | 001-36076    | 65-1311552          |
| (State or other jurisdiction of | (Commission  | (I.R.S. Employer    |
| incorporation)                  | File Number) | Identification No.) |

3535 General Atomics Court, Suite 200

Edgar Filing: FATE THERAPEUTICS INC - Form 8-K

San Diego, CA 92121

(Address of principal executive offices, including zip code)

(858) 875-1800

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Edgar Filing: FATE THERAPEUTICS INC - Form 8-K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 5, 2018, Chris Storgard notified Fate Therapeutics, Inc. (the “Company”) of his intent to step down as Chief Medical Officer effective as of such date. Dr. Storgard will continue to provide services to the Company through December 31, 2018 under a consulting agreement. The Company is conducting a search for a replacement.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2018

FATE THERAPEUTICS, INC.

By: /s/ J. Scott Wolchko  
J. Scott Wolchko  
President and Chief Executive Officer